GlassScriptPhysician profile
Adrian A Santamaria
NPI 1346444932
$140,945.62
in general payments reported to CMS, 2019-2025
50 companies · $25K in 2025
The $25K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $7,099 · 2021: $23K · 2022: $14K · 2023: $24K · 2024: $27K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $19K · Honoraria: $17K · Food and Beverage: $11K · Travel and Lodging: $4,136 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $25,375.00 |
| Consulting Fee | $18,937.00 |
| Honoraria | $16,700.00 |
| Food and Beverage | $10,825.70 |
| Travel and Lodging | $4,135.77 |
| Education | $370.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $89,196.79 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $23,135.96 | 2023-2025 | Lumryz |
| Inspire Medical Systems, INC. | $10,431.37 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $9,857.41 | 2023-2025 | Sunosi |
| Harmony Biosciences LLC | $2,320.97 | 2020-2025 | Wakix |
| Medtronic, INC. | $962.29 | 2022-2024 | Percept PC Brainsense, Activa PC |
| Abbvie INC. | $531.61 | 2022-2025 | Duopa, Qulipta, Ubrelvy |
| Eisai INC. | $458.68 | 2023-2025 | |
| Genentech USA, INC. | $363.71 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Sk Life Science, INC. | $282.70 | 2022-2025 | |
| Amgen INC. | $262.89 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $255.39 | 2021-2025 | |
| Pfizer INC. | $217.79 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $213.42 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Abbott Laboratories | $211.86 | 2021-2025 | Proclaim, Infinity, Eterna |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $168.82 | 2023-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $168.29 | 2022-2025 | Ingrezza, Ongentys |
| Amneal Pharmaceuticals LLC | $151.28 | 2022-2025 | Rytary, Crexont |
| Tg Therapeutics, INC. | $147.61 | 2024-2025 | |
| Grifols USA, LLC | $128.64 | 2023-2025 | Gamunex-C |
| Ucb, INC. | $107.48 | 2023-2025 | Rystiggo, Fintepla |
| Argenx US, INC. | $106.04 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Azurity Pharmaceuticals, INC. | $95.52 | 2023-2024 | Horizant, Horizant |
| Lilly USA, LLC | $93.41 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Biogen, INC. | $84.35 | 2021-2024 | Tysabri, Vumerity |
| Horizon Therapeutics Plc | $80.94 | 2021-2023 | Uplizna |
| Alexion Pharmaceuticals, INC. | $78.57 | 2023-2025 | Ultomiris |
| Emd Serono, INC. | $72.00 | 2022-2023 | Mavenclad |
| Livanova USA, INC. | $64.50 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $60.09 | 2023-2025 | Vyepti, Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $58.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.52 | 2023-2025 | Hyqvia |
| Aucta Pharmaceuticals, INC. | $55.94 | 2025 | Motpoly Xr |
| Astrazeneca Pharmaceuticals LP | $47.01 | 2022 | |
| Avion Pharmaceuticals | $44.65 | 2023 | Dhivy |
| Supernus Pharmaceuticals, INC. | $42.56 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $41.48 | 2025 | Rexulti |
| Zoll Respicardia, INC. | $37.65 | 2023-2025 | Remede System |
| Impel Pharmaceuticals LLC | $30.94 | 2025 | Trudhesa |
| Amylyx Pharmaceuticals, INC. | $25.05 | 2023 | Relyvrio |
| Life Molecular Imaging LTD | $24.81 | 2025 | Neuraceq |
| 3b Medical, INC. | $24.79 | 2025 | Luna |
| Celgene Corporation | $23.10 | 2025 | Zeposia |
| Philips North America LLC | $21.94 | 2025 | Home Pi Undivided |
| Xeris Pharmaceuticals, INC. | $20.27 | 2025 | Keveyis |
| Idorsia Pharmaceuticals US INC | $19.00 | 2024 | Quviviq |
| Janssen Pharmaceuticals, INC | $15.79 | 2022 | |
| Resmed Corp | $15.69 | 2024 | |
| Insightec,INC | $14.69 | 2024 | Exablate |
| Allergan, INC. | $14.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrian Santamaria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.